Versican expression in pharyngeal squamous cell carcinoma: An immunohistochemical study

Journal of Clinical Pathology

Volumn 57, Issue 7, 2004, Pages 735-739

  Pukkila, M J ^a   Kosunen, A S T ^a   Virtaniemi, J A ^a   Kumpulainen, E J ^a   Johansson, R T ^a   Kellokoski, J K ^a   Nuutinen, J ^a   Kosma, V M ^a,b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CATENIN; PROTEIN P53; PROTEOGLYCAN; VERSICAN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOPHARYNX TUMOR; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STAINING; STROMA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LECTINS, C-TYPE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PHARYNGEAL NEOPLASMS; PROGNOSIS; PROTEOCHONDROITIN SULFATES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VERSICANS;

EID: 3142596333     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.014589     Document Type: Article

References (36)

1. Schwartz NB, Pirok EW 3rd, Mensch JR Jr, et al. Domain organization, genomic structure, evolution, and regulation of expression of the aggrecan gene family. Prog Nucleic Acid Res Mol Biol 1999;62:177-225.
2. LeBaron RG, Zimmermann DR, Ruoslahti E. Hyaluronate binding properties of versican. J Biol Chem 1992;267:10003-10.
3. Zimmermann DR, Ruoslahti E. Multiple domains of the large fibroblast proteoglycan, versican. EMBO J 1989;8:2975-81.
4. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002;14:617-23.
5. Bode-Lesniewska B, Dours-Zimmermann MT, Odermatt BF, et al. Distribution of the large aggregating proteoglycan versican in adult human tissues. J Histochem Cytochem 1996;44:303-12.
6. Theocharis AD, Vynios DH, Papageorgakopaulou N, et al. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 2003;35:376-90.
7. Ricciardelli C, Brooks JH, Suwiwat S, et al. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 2002;8:1054-60.
8. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999;5:1041-56.
9. Voutilainen K, Anttila M, Sillanpää S, et al. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int J Cancer 2003;107:359-64.
10. Ricciardelli C, Mayne K, Sykes PJ, et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res 1998;4:963-71.
11. Touab M, Villena J, Barranco C, et al. Versican is differentially expressed in human melanoma and may play a role in tumour development. Am J Pathol 2002;160:549-57.
12. Gulyas M, Hjerpe A. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, eprthelioid mesothelioma, and benign mesothelium. J Pathol 2003;199:479-87.
13. Isogai Z, Shinomura T, Yamakawa N, et al. 2B1 antigen characteristically expressed on extracellular matrices of human malignant tumours is a large chondroitin sulfate proteoglycan, PG-M/versican. Cancer Res 1996;56:3902-8.
14. Paulus W, Baur I, Dours-Zimmerman MT, et al. Differential expression of versican isoforms in brain tumours. J Neuropathol Exp Neurol 1996;55:528-33.
15. Zhang Y, Cao L, Yang BL, et al. The G3 domain of versican enhances cell proliferation via epidermal growth factor-like motifs. J Biol Chem 1998;273:21342-51.
16. Ang LC, Zhang Y, Cao L, et al. Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 1999;58:597-605.
17. Yang BL, Zhang Y, Cao L, et al. Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 1999;72:210-20.
18. Sakko AJ, Ricciardelli C, Mayne K, et al. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res 2003;63:4786-91.
19. Sakko AJ, Ricciardelli C, Mayne K, et al. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor β1. Cancer Res 2001;61:926-30.
20. Yoon H, Liyanarachchi S, Wright FA, et al. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A 2002;99:15632-7.
21. Black RJ, Bray F, Ferlay J, et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997;33:1075-107.
22. Slootweg PJ, Richardson M. Squamous cell carcinoma of the upper aerodigestive system. In: Gnepp DR, ed. Diagnostic surgical pathology of the head and neck. Philadelphia: WB Sounders, 2001:19-78.
23. Berrino F, Gatta G. Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. EUROCARE working group. Eur J Cancer 1998;34:2154-61.
24. Pukkila MJ, Virtaniemi JA, Kumpulainen EJ, et al. Nuclear β catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin Pathol 2001;54:42-7.
25. Pukkila MJ, Kumpulainen EJ, Virtaniemi JA, et al. Nuclear and cytoplasmic p53 expression in pharyngeal squamous cell carcinoma: prognostic implications. Head Neck 2002;24:784-91.
26. Pharynx. In: Sobin LH, Wittekind C, eds. TNM classification of malignant tumours, 5th ed. New York: Wiley-Liss, 1997:25-32.
27. Karnofsky DA, Abelmann WH, Craver LF, et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-56.
28. Shanmugaratnam K. Histological typing of tumours of the upper respiratory-tract and ear, 2nd ed. Berlin: Springer, 1991.
29. Zimmermann DR, Dours-Zimmermann MT, Schubert M, et al. Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 1994;124:817-25.
30. Karvinen S, Kosma VM, Tammi MI, et al. Hyaluronan, CD44 and versican in epidermal keratinocyte tumours. Br J Dermatol 2003;148:86-94.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
32. Cox DR. Regression models and life tables with discussion. Journal of the Royal Statistical Society Series B Methodological 1972;34:187-92.
33. Touab M, Arumi-Uria M, Barranco C, et al. Expression of the proteoglycans versican and mel-CSPG in dysplastic nevi. Am J Clin Pathol 2003;119:587-93.
34. van den Brekel MWM, Bindels EMJ, Balm AJM. Prognostic factors in head and neck cancer. Eur J Cancer 2002;38:1041-3.
35. Banerjee AG, Liu J, Yuan Y, et al. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Mol Cancer 2003;2:34.
36. Bargonetti J, Manfredi JJ. Multiple roles of the tumour suppressor p53. Curr Opin Oncol 2002;14:86-91.